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Abstract
Background: Brain stem cardiovascular regulatory dysfunction during brain death is underpinned by an upregulation of nitric
oxide synthase II (NOS II) in rostral ventrolateral medulla (RVLM), the origin of a life-and-death signal detected from blood
pressure of comatose patients that disappears before brain death ensues. Furthermore, the ubiquitin-proteasome system
(UPS) may be involved in the synthesis and degradation of NOS II. We assessed the hypothesis that the UPS participates in
brain stem cardiovascular regulation during brain death by engaging in both synthesis and degradation of NOS II in RVLM.
Methodology/Principal Findings: In a clinically relevant experimental model of brain death using Sprague-Dawley rats,
pretreatment by microinjection into the bilateral RVLM of proteasome inhibitors (lactacystin or proteasome inhibitor II)
antagonized the hypotension and reduction in the life-and-death signal elicited by intravenous administration of Escherichia
coli lipopolysaccharide (LPS). On the other hand, pretreatment with an inhibitor of ubiquitin-recycling (ubiquitin aldehyde)
or ubiquitin C-terminal hydrolase isozyme L1 (UCH-L1) potentiated the elicited hypotension and blunted the prevalence of
the life-and-death signal. Real-time polymerase chain reaction, Western blot, electrophoresis mobility shift assay, chromatin
immunoprecipitation and co-immunoprecipitation experiments further showed that the proteasome inhibitors antagonized
the augmented nuclear presence of NF-kB or binding between NF-kB and nos II promoter and blunted the reduced
cytosolic presence of phosphorylated IkB. The already impeded NOS II protein expression by proteasome inhibitor II was
further reduced after gene-knockdown of NF-kB in RVLM. In animals pretreated with UCH-L1 inhibitor and died before
significant increase in nos II mRNA occurred, NOS II protein expression in RVLM was considerably elevated.
Conclusions/Significance: We conclude that UPS participates in the defunct and maintained brain stem cardiovascular
regulation during experimental brain death by engaging in both synthesis and degradation of NOS II at RVLM. Our results
provide information on new therapeutic initiatives against this fatal eventuality.
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Introduction
Brain death, the legal definition of death in many countries [1–
3], is commonly recognized as a neurological phenomenon. Two
clinical observations, however, in effect place brain death into the
realm of circulatory research. First, asystole invariably takes place
within hours or days after the diagnosis of brain death [4]. Second,
a unique prognostic phenotype for life-and-death exists in the low-
frequency (LF) component (0.04–0.15 Hz in human) of systemic
arterial pressure (SAP) spectrum. The power density of the LF
component, which mirrors the prevalence of baroreflex-mediated
sympathetic neurogenic vasomotor tone [5], undergoes a dramatic
reduction or loss before brain death ensues in comatose patients
[6–8] to reflect irreversible failure of brain stem cardiovascular
regulatory functions [9]. It follows that delineation of the
mechanisms that underpin the shift between maintained and
defunct brain stem cardiovascular regulatory machinery during
the progression towards brain death should shed further light on
this fatal phenomenon. That the LF component originates from
the rostral ventrolateral medulla (RVLM) [10], which is known
classically for its role in tonic maintenance of vasomotor tone and
SAP [11], allows this brain stem site to be a suitable neural
substrate for such a mechanistic delineation [9].
It is now clear that most proteins in the cytoplasm and nucleus
of eukaryotic cells are degraded via the ubiquitin-proteasome
system (UPS) [12,13]. The highly conserved 76 amino acid protein
ubiquitin is best known for its role in targeting proteins for
degradation by the 26S proteasome. Conjugation of ubiquitin to
the protein substrate during ubiquitination proceeds via a three-
step mechanism. The ubiquitin-activating enzyme, E1, first
activates ubiquitin. Following activation, one of several ubiqui-
tin-conjugating enzymes (E2) transfers ubiquitin from E1 to a
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substrate protein is specifically bound. Polyubiquitinated proteins
are recognized by the regulatory 19S complexes of the protea-
some, which unfold the protein substrates and assist in their
translocation through a narrow gate into the 20S core where
degradation takes place. Following conjugation, the protein moiety
of the adduct is degraded by the 26S proteasome complex. After
the degradative process at the 26S proteasome, the ubiquitin chain
is released from the target protein remnant and is disassembled by
de-ubiquitinating enzymes, including the ubiquitin C-terminal
hydrolases (UCHs) [14]. The UCHs are responsible for the
removal of small peptide fragments from the ubiquitin chain and
for co-translational processing of ubiquitin gene products to
generate free monomeric ubiquitin [14,15]. Of the three known
mammalian members of the UCH family, UCH isozyme-L1
(UCH-L1) is among the most abundantly present proteins in brain
[16]. One of the best-known targets of the UPS is activation of the
inducible transcription factor nuclear factor-kB (NF-kB) [17,18].
NF-kB is retained in a latent form in the cytoplasm of non-
stimulated cells by inhibitory molecules collectively termed
inhibitory-kB( I kB). Stimuli that induce NF-kB activation target
IkB to site-specific phosphorylation, leading to its degradation by
the UPS. Following IkB degradation, NF-kB is translocated to the
nucleus as an active transcription factor that is able to induce its
target genes.
In an animal model that employs Escherichia coli lipopolysaccha-
ride (LPS) as the experimental insult [19–21], our laboratory
found previously that the dysfunction of brain stem cardiovascular
regulatory machinery as reflected by the reduction in the power
density of the LF component during the advancement towards
brain death is associated with the progressive augmentation in
both molecular synthesis and functional expression of nitric oxide
synthase II (NOS II) in RVLM. We further showed that
transcriptional regulation by NF-kB is crucial to the expression
of NOS II gene [20]. At the same time, scattered reports suggest
that the UPS may also be involved in the degradation of NOS II
Figure 1. UPS in RVLM participates in brain stem cardiovascular regulation during experimental brain death. Temporal changes in
mean systemic arterial pressure (MSAP), heart rate (HR) or power density of the low-frequency (LF) component of SAP signals in rats that received
pretreatment by microinjection bilaterally into RVLM of lactacystin (Lacta; 1 nmol) (A), proteasome inhibitor II (PiII; 1 nmol) (B) or their solvents
(Vehicle), followed by IV administration (at arrows) of LPS (15 mg kg
21) or saline. Values are mean 6 SEM; n=7–8 animals per group. *P ,0.05 versus
Vehicle+Saline group, and
+P ,0.05 versus Vehicle+LPS group at corresponding time-points in the Scheffe ´ multiple-range test. C, baseline.
Demarcation of Phases I, II and III according to the decrease, increase and secondary decrease of LF power is shown on top of the diagrams.
doi:10.1371/journal.pone.0027404.g001
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stem cardiovascular control during brain death by engaging in
both the synthesis and degradation of NOS II in RVLM. This
hypothesis is validated based on an experimental endotoxemia
model.
Results
UPS in RVLM participates in brain stem cardiovascular
regulation during experimental brain death
An experimental endotoxemia model of brain death [9] that
mimics clinically the progression towards brain death in patients
died of systemic inflammatory response syndrome [7] was used.
As reported previously [19–21], based on the decrease, increase,
and a secondary decrease in the power density of the LF
component in the SAP spectrum, which reflect lower or higher
probability of defunct or maintained brain stem circulatory
regulation, the sequence of cardiovascular responses induced by
intravenous administration of LPS (15 mg kg
21) can be divided
into three phases (Figure 1). SAP underwent typically a
significant decrease and a rebound during Phase I, to be
followed by progressive hypotension during Phases II and III
endotoxemia. Fluctuations in heart rate (HR) were insignificant.
Intriguingly, inhibiting proteasome activities by microinjection
bilaterally of a non-selective proteasome inhibitor [24], lacta-
cystin (1 nmol; Figure 1A) or a specific inhibitor of chymotryp-
sin-like proteasomal activity [25], proteasome inhibitor II
(1 nmol; Figure 1B) into RVLM significantly antagonized the
elicited hypotension. The increase in power density of LF
component of SAP signals during Phase II endotoxemia was
potentiated, and the decrease in LF power during Phase III was
significantly blunted.
Drastic difference between upregulation of NOS II mRNA
and protein in RVLM during experimental brain death
Our laboratory demonstrated previously [19–21] that upregu-
lation of NOS II in RVLM underlies brain stem cardiovascular
regulatory dysfunction in our experimental endotoxemia model
of brain death. Whether this NOS isoform is a target for post-
translational modification by the UPS was investigated in our
second series of experiments. Real-time polymerase chain
reaction (PCR) analysis revealed significant and progressive
augmentation of nos II mRNA in RVLM, reaching approximately
22 folds over sham-controls during Phase III (Figure 2A).
Whereas protein expression of NOS II as determined by
Western-blot analysis also underwent a gradual increase
(Figure 2B), it amounted to only 1.3 folds over sham-controls
during Phase III.
UPS is engaged in the synthesis of NOS II at RVLM
An upregulation of NOS II through NF-kBa c t i v a t i o ni n
RVLM [20] plays a pivotal role in our experimental endotox-
emia model of brain death. As such, the UPS may participate in
the synthesis of NOS II via its regulatory role in NF-kB
activation [17,18]. Results from electrophoresis mobility shift
assay (EMSA) (Figure 3A) showed a significant and progressive
increase in the association of NF-kB with its consensus DNA
oligonucleotide in nuclear extracts from RVLM during exper-
imental brain death. We confirmed that this association was not
due to non-specific binding when competitive assay using
unlabeled NF-kB oligonucleotide resulted in appreciable disap-
pearance of NF-kB DNA binding (Figures 3A and S1). Super-
shift experiments further revealed specific binding by showing
that an anti-NFkB p50 antiserum retarded the migration of
proteins that interacted with the NF-kB oligonucleotide (Figure
S1). Intriguingly, microinjection bilaterally of lactacystin
(1 nmol) or proteasome inhibitor II (1 nmol) into RVLM
discernibly antagonized the augmented nuclear presence of
NF-kB (Figure 3A). In addition, both proteasome inhibitors
significantly antagonized the reduced phosphorylated IkB( p I kB)
level in cytosolic fraction of extracts from RVLM during Phase
III (Figure 3B). Co-immunoprecipitation experiments also
indicated that the association between ubiquitin and pIkBi n
the cytosol was significantly strengthened in the presence of
proteasome inhibitor II (Figure 3B). Results from chromatin
immunoprecipitation (ChIP) assay using an anti-NFkBp 6 5
antiserum further ascertained a progressively augmented binding
between NF-kBa n dnos II promoter in RVLM, which was
significantly antagonized by lactacystin or proteasome inhibitor
II (Figure 4A). This implicated crucial involvement of UPS-
mediated IkB degradation in the synthesis of NOS II was further
Figure 2. Drastic difference between upregulation of NOS II
mRNA and protein in RVLM. Illustrative gels or summary of fold
changes against sham-controls in nos II mRNA determined by real-time
PCR (A) or NOS II protein detected by Western blot analysis (B) in
ventrolateral medulla of rats that received IV administration of LPS
(15 mg kg
21). Values are mean 6 SEM of triplicate (mRNA) or duplicate
(protein) analyses on individual samples obtained from 5–6 animals per
experimental group. *P ,0.05 versus sham-control group in the Scheffe ´
multiple-range test.
doi:10.1371/journal.pone.0027404.g002
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real-time PCR analysis (Figure 4B).
UPS is also engaged in the degradation of NOS II at RVLM
Our fourth series of experiments delineated whether the UPS is
also engaged in the degradation of NOS II in RVLM, as
suggested by the drastic disparity of the upregulated mRNA and
protein levels. Figure 5A shows that in the presence of lactacystin
(1 nmol), the protein expression of NOS II in RVLM during
Phases I and II was significantly augmented, although there was
no further increase during Phase III experimental brain death.
Pretreatment with proteasome inhibitor II (1 nmol) completely
antagonized the progressive increase in NOS II protein
expression (Figure 5B). Intriguingly, gene-knockdown of NF-kB
with kB decoy DNA not only blunted the significantly augmented
NOS II protein expression when compared to kB scrambled
DNA controls, but further reduced it to a level that was
significantly below that in the proteasome inhibitor II-pretreat-
ment group (Figure 5C).
De-ubiquitination is crucially involved in maintaining
brain stem cardiovascular regulation during
experimental brain death
Pretreatment by microinjection bilaterally into RVLM of a
general inhibitor of ubiquitin-recycling [26], ubiquitin aldehyde
(50 fmol) or a potent, reversible, competitive and active site-
directed UCH-L1 inhibitor [27], (1 nmol), significantly potentiat-
ed the elicited hypotension, initiated bradycardia and blunted the
increase in power density of LF component during the significantly
shortened Phase II experimental brain death (Figure 6).
De-ubiquitination is crucially involved in degradation of
NOS II at RVLM
Our final series of experiments determined whether de-
ubiquitination is more engaged in degradation or synthesis of
NOS II. Animals that received pretreatment with UCH-LI
inhibitor (1 nmol) and succumbed to LPS within 5–10 min after
administration demonstrated that in the absence of significant
Figure 3. UPS is engaged in the synthesis of NOS II via transcriptional activation of NF-kB in RVLM. (A) Representative gels depicting NF-
kB DNA binding detected by EMSA in nuclear extracts from ventrolateral medulla of rats that received pretreatment by microinjection bilaterally into
RVLM of lactacystin (Lacta; 1 nmol) or aCSF (upper diagram), or proteasome inhibitor II (PiII; 1 nmol) or DMSO (lower diagram), followed by IV
administration of LPS (15 mg kg
21). A competitive assay with the addition of 100-fold of unlabeled NF-kB oligonucleotide was used to control for
non-specific binding (Cold). In both gels, ns denotes non-specific binding. (B) Illustrative gels or summary of fold changes against sham-controls of
phosphorylated IkBa (p-IkBa) in cytosolic proteins detected by Western blot analysis (upper diagram) or immunoblot analysis of p-IkBa
immunoprecipitated by an anti-ubiquitin (Ub) antiserum (lower diagram) during Phase III experimental endotoxemia in rats that received those
treatments depicted in (A). Values are mean 6 SEM of duplicate analyses on individual samples obtained from 5–6 animals per experimental group.
*P ,0.05 versus sham-control group, and
+P ,0.05 versus aCSF+LPS or DMSO+LPS group in the Scheffe ´ multiple-range test.
doi:10.1371/journal.pone.0027404.g003
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RVLM was augmented by more than 50% (Figure 7B). There was
also significantly elevated ubiquitinylated NOS II in RVLM
(Figure 7C), alongside augmented nitrotyrosine (Figure 7D), an
experimental index for peroxynitrite that underlies fatality in
experimental brain death [20,21].
Discussion
The fundamental premise of the present study is that the
progression from maintained to defunct brain stem cardiovascular
regulation during the advancement of brain death is underpinned
by the progressive increase in NOS II level in RVLM [19–21].
Based on an endotoxemia model of experimental brain death, our
results revealed a novel, causal and double-edged sword role for
the UPS at RVLM in this process (Figure 8A). Specifically, we
demonstrated that a crucial determinant in the tug-of-war between
maintained and defunct brain stem circulatory regulation during
brain death resides in the temporal balance between the
continuous degradation of NOS II and the progressively
augmented synthesis of the isozyme in RVLM (Figure 8B). We
further found that recycling of ubiquitin in RVLM through
sustained de-ubiquitination is crucial to uninterrupted degradation
of NOS II, which is essential for the maintenance of brain stem
cardiovascular control.
Our laboratory demonstrated previously that an upregulation of
NOS II through NF-kB activation at RVLM [20] plays a pivotal
role in eliciting defunct brain stem cardiovascular regulation
during experimental endotoxemia. The nos II gene is potentially
regulated transcriptionally by NF-kB [28–30] because NF-kB-
binding sites are present in the rat [29] or mouse [31] nos II
promoter, and are considered to be critical for gene expression. Of
note is that activation of NF-kB is one of the best-known targets of
the UPS [17,18]. Site-specific phosphorylation of IkB, which leads
to its degradation by the UPS, allows NF-kB to be translocated to
the nucleus as an active transcription factor that is able to induce
its target genes. Our results from EMSA, ChIP assay, co-
immunoprecipitation and real-time PCR showed that this
repertoire of cellular events indeed takes place during experimen-
tal brain death, leading to the synthesis of NOS II in RVLM.
The physiological importance of degradation of NOS II by the
UPS has been shown in Dahl/Rapp salt-sensitive rats [23]. The
26S proteasome was identified [32] to be the primary degradation
site for NOS II in human epithelial kidney HEK293 cells and
murine macrophage cell line RAW 264.7; ubiquitination is
required for this degradative process [22]. It is therefore
conceivable that continuous degradation by the UPS may account
for the moderate increase in NOS II protein despite drastically
augmented nos II mRNA in RVLM during experimental brain
death. Whereas our observations after lactacystin pretreatment
(Figure 5A) support this notion, our results from proteasome
inhibitor II (Figure 5B) suggest otherwise. Furthermore, pretreat-
ments with proteasome inhibitors may prevent NOS II synthesis in
RVLM by reducing IkB degradation, leading to an increase in
association between NF-kB and IkB in the cytoplasm, which
prevents nuclear translocation of NF-kB. This riddle was resolved
by knockdown of NF-kB gene with kB decoy DNA (Figure 5C). In
the absence of NOS II synthesis via NF-kB activation, the
significant reduction from the already impeded NOS II protein
expression in RVLM of the proteasome inhibitor II-pretreatment
group lends support to the notion that degradation of NOS II
indeed takes place in RVLM during experimental brain death.
The differential effects of lactacystin and proteasome inhibitor II
also infer that chymotrypsin-like activity in the proteasome may be
primarily responsible for the degradation of NOS II in RVLM.
Our laboratory found previously that peroxynitrite formed by a
reaction between NOS II-derived NO and superoxide anion
underlies the dysfunctional brain stem cardiovascular regulation in
our experimental endotoxemia model of brain death [20,21].
Intriguingly, we found that whereas degradation of NOS II
protein was maintained throughout our 240-min observation
period, synthesis of this isoform via NF-kB activation following
IkB degradation became prevalent only during Phases II and III.
The resultant progressive increase in NOS II protein in RVLM,
which favors the production of peroxynitrite that leads to
cardiovascular depression, is commensurate with the observation
that pretreatment with the proteasome inhibitors significantly
antagonized the progressive hypotension and decrease in LF
power, and improved survival rate during experimental brain
death. We are aware that overexpression of NOS II in RVLM
reportedly induces pressor and sympathoexcitatory response [33].
As such, the possibility exists for the initial increase in NOS II
Figure 4. NF-kB transcriptionally activated by UPS binds to nos
II promoter in RVLM. Phasic fold changes against sham-controls in
(A) binding between NF-kB and nos II promoter measured by ChIP
assay, or (B) nos II mRNA level determined by real-time PCR analysis in
ventrolateral medulla of rats that received pretreatment by microinjec-
tion bilaterally into RVLM of lactacystin (Lacta; 1 nmol), proteasome
inhibitor II (PiII; 1 nmol) or their solvent (vehicle), followed by IV
administration of LPS (15 mg kg
21). Values are mean 6 SEM of triplicate
analyses on individual samples obtained from 5–6 animals per
experimental group. *P ,0.05 versus sham-control group, and
+P
,0.05 versus Vehicle+LPS group at corresponding phases in the Scheffe ´
multiple-range test.
doi:10.1371/journal.pone.0027404.g004
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Phase II endotoxemia.
Optimal operation of polyubiquitination also depends on the
availability of monoubiquitin (free form of ubiquitin), which is
regulated by the de-ubiquitinating enzymes [14]. By showing the
effectiveness of ubiquitin aldehyde at fmol concentration to
exacerbate cardiovascular depression, the present study revealed
that recycling of ubiquitin in RVLM is vitally involved in the
maintenance of brain stem cardiovascular regulatory functions in
our experimental endotoxemia model of brain death. Of the
known de-ubiquitination enzymes, UCH-L1 is among the most
abundantly present proteins in brain [16]. The present study
showed that on an equimolar basis (1 nmol), the degree of
amelioration of defunct brain stem cardiovascular regulation by
lactacystin or proteasome inhibitor II was significantly less than
the detrimental effects of UCH-L1 inhibitor. This result is
interpreted to imply that de-ubiquitination by UCH-L1 in
RVLM plays a maintenance role in brain stem cardiovascular
regulation during experimental brain death. Animals in which
recycling of ubiquitin in RVLM was inhibited and died within 5–
10 min of LPS administration provided a golden opportunity to
delineate the underlying mechanism. The 50% increase in NOS
II protein expression in RVLM at a time when there was no
significant increase in nos II mRNA, alongside elevated
ubiquitinylated NOS II and augmented nitrotyrosine, amply
supports the notion that the free forms of ubiquitin availed by
UCH-L1 is targeted for degradation of NOS II. In addition,
UCH-L1 may also reduce NOS II synthesis by attenuation of
NF-kB activation [34].
We are cognizant that LPS also activates NF-kBt h a tl e a d st o
the synthesis of NOS II in peripheral tissues [30]. In this regard,
our clinical experience [7] is that a dramatic reduction or loss of
the power density of the LF component consistently takes place
before significant hypotension occurs during the progression
towards brain death in patients who succumbed to systemic
inflammatory response syndrome, followed by asystole. This
suggests that synthesis of NOS II via activation of NF-kBi n
RVLM, leading to a reduction in LF power that results in
defunct brain stem cardiovascular regulation may play a pivotal
role in our experimental endotoxemia model of brain death.
The design of our study did not allow us to decipher the cell
types in RVLM that were affected by LPS. Nevertheless,
previous studies from our laboratory [35] showed that NOS II is
activated by LPS in neurons, astrocytes and microglia in
RVLM.
T h eU P Sh a se m e r g e di nr e c e n ty e a r sa sac e n t r a lp l a y e ri n
the modulation of cell fate [36] and cell death pathways [37].
Aberrations in either the process of ubiquitination or de-
ubiquitination have also been directly implicated in the etiology
of many diseases [13], including cardiomyopathy [38]. It is
therefore of interest that the present study provided novel
findings to support the notion that the UPS participates in the
defunct and maintained brain stem cardiovascular regulation by
engaging in both synthesis and degradation of NOS II at
RVLM during experimental brain death. We further found that
recycling of ubiquitin in RVLM through sustained de-ubiqui-
Figure 5. UPS is also engaged in the degradation of NOS II at
RVLM. Illustrative gels or summary of fold changes against sham-
controls of NOS II proteins detected by Western blot analysis in
ventrolateral medulla of rats that received pretreatment by microinjec-
tion bilaterally into RVLM of lactacystin (Lacta; 1 nmol) or aCSF (A),
proteasome inhibitor II (PiII; 1 nmol) or DMSO (B) or scrambled or decoy
kB DNA (C), followed by IV administration of LPS (15 mg kg
21). Values
are mean 6 SEM of duplicate analyses on individual samples obtained
from 5–6 animals per experimental group. *P ,0.05 versus sham-
control group, and
+P ,0.05 versus aCSF+LPS or DMSO+LPS group at
corresponding phases (A, B); or *P ,0.05 versus sham-control group,
#P
,0.05 versus PiII+LPS group and
+P ,0.05 versus scrambled kB DNA
+LPS group (C) in the Scheffe ´ multiple-range test.
doi:10.1371/journal.pone.0027404.g005
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invaluable to future development of management strategies
against fatal eventualities such as brain death. It also posts a
cautionary note on using the UPS as a therapeutic target
because of the potential double-edged sword actions on its
protein substrates.
Materials and Methods
Ethics Statement
All experimental procedures carried out in this study have been
approved by the Institutional Animal Care and Use Committees of
the National Sun Yat-sen University and Kaohsiung Chang Gung
Memorial Hospital (#96008), and were in compliance with the
guidelines for animal care and use set forth by those committees.
All efforts were made to minimize animal suffering and to reduce
the number of animal used.
Animals
Adult, male Sprague-Dawley rats (2022255 g; n=518) were
purchased from the Experimental Animal Center of the National
Applied Research Laboratories, Taiwan. They were housed in an
Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC) International-accredited animal facility
under temperature control (24 6 0.5uC) and 12-h light-dark cycle
(lights on during 08:00–20:00). Standard laboratory rat chow and
tap water were available ad libitum. Animals were allowed to
acclimatize for at least 7 days prior to experimental manipulations.
General preparation
Under initial pentobarbital sodium anesthesia (50 mg kg
21, IP),
the trachea was intubated and the right femoral artery and both
femoral veins were cannulated. Animals received thereafter IV
infusion of propofol (Zeneca, Macclesfield, UK) at 20 mg
kg
21 h
21. This scheme provides satisfactory anesthetic mainte-
nance while preserving the capacity of brain stem cardiovascular
regulation [39]. The head of animals was fixed to a stereotaxic
headholder (Kopf, Tujunga, CA), and body temperature was
maintained at 37uC with a heating pad. Animals were allowed to
breathe spontaneously with room air during the recording session.
Recording and power spectral analysis of systemic
arterial pressure signals
SAP signals recorded from the femoral artery were subject to
on-line and real-time power spectral analysis [40]. HR was
estimated instantaneously from the digitized SAP signals. We were
particularly interested in the LF component (0.25–0.8 Hz) in the
SAP spectrum for three reasons. First, its power density mirrors
the prevalence of baroreflex-mediated sympathetic neurogenic
vasomotor discharges [5] that emanate from this brain stem site
[11] and is therefore a reasonable index for brain stem
cardiovascular regulation. Second, it takes origin from RVLM
[10]. Third and most importantly, the power density of the LF
component represents the most crucial link between our animal
model and clinical observations from patients who died of systemic
inflammatory response syndrome [7], and is a more sensitive
prognostic index than SAP for brain death [9].
Experimental endotoxemia model of brain death
An experimental endotoxemia model of brain death [9], which
mimics clinically the progression towards brain death in patients
died of systemic inflammatory response syndrome [7] was used.
Escherichia coli LPS (serotype 0111:B4, Sigma-Aldrich, St. Louis,
MO) was administered intravenously (15 mg ˙kg
21), with saline
serving as the vehicle control. Temporal changes in pulsatile SAP,
mean SAP (MSAP), HR and power density of the LF component
were routinely followed for 240 min, in an on-line and real-time
manner [40]. As we reported previously [20,21,41], the sequence
of cardiovascular events during this LPS-induced endotoxemia can
be divided into a reduction (Phase I), followed by an augmentation
Figure 6. De-ubiquitination is crucially involved in maintaining
brain stem cardiovascular regulation during experimental
brain death. Temporal changes in MSAP, HR or power density of
the LF component of SAP signals in rats that received pretreatment by
microinjection bilaterally into RVLM of ubiquitin aldehyde (UbAd), UCH-
L1 inhibitor (UCH-L1i) or their solvents (Vehicle), followed by IV
administration (at arrows) of LPS (15 mg kg
21) or saline. Values are
mean 6 SEM; n=7–8 animals per group. *P ,0.05 versus Vehicle+Sa-
line group, and
+P ,0.05 versus Vehicle+LPS group at corresponding
time-points in the Scheffe ´ multiple-range test. C, baseline.
doi:10.1371/journal.pone.0027404.g006
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density of the LF component of SAP signals. This triphasic change
in LF power can be used to reflect lower or higher probability of
defunct or maintained brain stem circulatory regulation during
experimental brain death. There was also progressive hypotension,
with death ensuing generally within 4 h in approximately 40% of
the animals.
Microinjection of test agents into RVLM
To produce site-specific actions, test agents were microinjected
bilaterally and sequentially into RVLM via a glass micropipette
connected to a 0.5-ml Hamilton (Reno, NV) microsyringe
[5,20,21,41]. The coordinates used were: 4.5 to 5 mm posterior
to the lambda, 1.8 to 2.1 mm lateral to the midline and 8.1 to
8.4 mm below the dorsal surface of the cerebellum. These
coordinates were selected to cover the ventrolateral medulla at
which functionally identified sympathetic premotor neurons
reside. Functional location of RVLM neurons was carried out at
the beginning of each experiment by the elicitation of a transient
increase in SAP (15–20 mmHg) on microinjection of glutamate.
As a routine, a total volume of 50 nl was delivered to each side of
RVLM over 2–3 min to allow for complete diffusion of the test
agents.
Test agents used included a non-selective proteasome inhibitor
[24], lactacystin (Calbiochem, San Diego, CA); a specific inhibitor
of chymotrypsin-like proteasomal activity [25], proteasome
inhibitor II (Calbiochem); a general inhibitor of ubiquitin-
recycling [26], ubiquitin aldehyde (Calbiochem); a potent,
reversible, competitive and active site-directed inhibitor of
UCH-L1 [27], (Calbiochem); and double-stranded kB decoy
DNA (5’-GAGGGGACTTTCCCT-3’) or its scrambled sequence
(5’-GATGCGTCTGTCGCA-3’) (Quality Systems, Taipei, Tai-
wan) [20]. The doses were adopted from previous reports that
used those test agents for the same purpose as in this study. Test
agents were dissolved in artificial cerebrospinal fluid (aCSF), with
the exception of proteasome inhibitor II and UCH-L1 inhibitor,
which was dissolved in 10% and 40% DMSO. Possible volume
effect of microinjection was controlled by injecting the same
amount of solvent. All test agents or their vehicles were given
30 min before LPS administration, with the exception that double-
stranded kB decoy DNA or its scrambled sequence was given 24 h
prior to LPS treatment. To avoid the confounding effects of drug
interactions, each animal received only one test agent.
Collection of tissue samples from RVLM
We routinely collected tissue samples from RVLM [20,21,41] at
the peak of each phase of experimental endotoxemia (LPS group)
or 15 min, 1.5 h or 3 h after IV injection of saline (vehicle group);
or immediately after animals succumbed to our experimental
treatments. Medullary tissues collected from anesthetized animals
but without treatment served as sham-controls. As a routine,
microinjection sites were visually verified and recorded after the
Figure 7. De-ubiquitination is crucially involved in degradation of NOS II at RVLM. Illustrative gels or summary of fold changes against
sham-controls in nos II mRNA determined by real-time PCR (A), NOS II protein detected by Western blot analysis (B), immunoblot analysis of NOS II
immunoprecipitated by an anti-ubiquitin (Ub) antiserum (C) or nitotyrosine determined by ELISA (D) in ventrolateral medulla of rats that received
pretreatment by microinjection bilaterally into RVLM of UCH-L1 inhibitor (UCH-L1i) or DMSO, during Phase I experimental endotoxemia induced by IV
administration (at arrows) of LPS (15 mg kg
21). Values are mean 6 SEM of triplicate (mRNA) or duplicate (protein) analyses on individual samples
obtained from 5–6 animals per experimental group. *P ,0.05 versus DMSO-control group in the Scheffe ´ multiple-range test.
doi:10.1371/journal.pone.0027404.g007
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rostral to the obex) was obtained. Tissues from both sides of the
ventrolateral medulla were subsequently collected by micro-
punches made with a 1 mm (id) stainless steel bore to cover the
anatomical boundaries of RVLM. In some experiments, proteins
from the nuclear or cytosolic fraction of the medullary samples
were extracted by a commercial kit (Active Motif, Carlsbad, CA).
The concentration of total or fractional proteins extracted was
determined by the BCA Protein Assay (Pierce, Rockford, IL).
Western blot analysis
Western blot analysis [20,21,41–44] was carried out using a
rabbit polyclonal antiserum against NOS II (Santa Cruz, Santa
Cruz, CA); or a mouse monoclonal antiserum against p-IkBa
(Santa Cruz) or b-actin (Chemicon, Temecula, CA). This was
followed by incubation with horseradish peroxidase-conjugated
donkey anti-rabbit IgG (Amersham Biosciences, Little Chalfont,
Bucks, UK) for NOS II; or sheep anti-mouse IgG (Amersham
Biosciences) for p-IkBa or b-actin. Specific antibody-antigen
complex was detected by an enhanced chemiluminescence
Western blot detection system (Santa Cruz). The amount of
protein was quantified by the ImageMaster Video Documentation
System software (Amersham Biosciences, City, NJ), and was
expressed as the ratio relative to b-actin protein.
Immunoprecipitation and immunoblot analysis
Protein extracts from the cytosolic fraction of samples from
RVLM were immunoprecipitated with affinity-purified mouse
monoclonal anti-ubiquitin antiserum conjugated with protein G-
agarose beads (Roche Diagnostics, Mannheim, Germany). Immu-
noprecipitation was performed [42] at 4uC overnight and the
precipitated beads obtained after being centrifuged for 5 s at
6,000 g were washed three times with ice-cold lysis buffer. The
agarose beads resuspended in the loading buffer were boiled for
5 min to dissociate the immunocomplexes from the beads.
Western blot analysis of p-IkB or NOS II from proteins
immunoprecipitated by an anti-ubiquitin antiserum was carried
out as described above.
Isolation of RNA and real-time PCR
Total RNA from RVLM was isolated with TRIzol reagent
(Invitrogen, Carlsgad, CA) [20,21,41–43]. All RNA isolated was
quantified by spectrophotometry and the optical density (OD)
260/280 nm ratio was determined. As in our previous studies [41–
43], reverse transcriptase reaction was performed using a
SuperScript Preamplification System (Invitrogen) for the first-
strand cDNA synthesis. Real-time PCR analysis was performed by
amplification of cDNA using a LightCycler
H instrument (Roche).
PCR reaction for each sample was carried out in duplicate for all
the cDNA and for the GAPDH control. Primers were designed
using the sequence information of the NCBI database by Roche
LightCycler
H probe design software 2.0, and oligonucleotides were
synthesized by Genemed Biotechnologies (Taipei, Taiwan).
The primer pairs used for amplification of target genes were:
nos II: 5’-TGGAGGTGCTGGAAGAGTT-3’ (forward primer)
and 5’-GGAGGAGCTGATGGAGTAGT-3’ (reverse primer);
GAPDH: 5’-GCCAAAAGGGTCATCATCTC-3’ (forward
primer) and 5’-GGCCATCCACAGTCTTCT-3’ (reverse prim-
er).
Fluorescence signals from the amplified products were quanti-
tatively assessed using the LightCycler
H software program (version
3.5; Roche). Second derivative maximum mode was chosen with
baseline adjustment set in the arithmetic mode. The relative
changes in nos II mRNA expression were determined by the fold-
Figure 8. Schematic illustration of a double-edge sword role
for the UPS in brain stem cardiovascular regulation during
experimental brain death. A crucial determinant in the tug-of-war
between maintained and defunct brain stem circulatory control resides
in the balance between degradation and synthesis (via NF-kB
activation) of NOS II, both processes of which require augmented
ubiquitination, enhanced proteasome activities and de-ubiquitination
in RVLM.
doi:10.1371/journal.pone.0027404.g008
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2[dd
Ct], where
ddCt =(Ctnos II 2 CtGAPDH)LPS treatment 2 (Ctnos II 2
CtGAPDH)sham control). Note that Ct value is the cycle number at
which fluorescence signal crosses the threshold.
Nuclear protein extraction and EMSA
We employed EMSA [20,44] to measure NF-kB DNA binding
activity in nuclear proteins pooled from ventrolateral medulla of 5
to 6 rats. The 3’ end of a double-stranded synthetic oligonucleotide
probe for NF-kB (5’-AGTGAGGGGACTTTCCCAGGC-3’ and
3’-TCAACTCCCCTGAAAGGGTCCG-5’) [20,44] was labeled
with digoxigenin-11-ddUTP (Roche). DNA and protein complexes
resolved on 4% polyacrylamide gels by electrophoresis were
detected by chemiluminescence after reacting with an anti-
digoxigenin antiserum (Roche). Competitive assay using unlabeled
NF-kB oligonucleotide served as the negative control. Antiserum
against NF-kB p50 subunit was used in supershift assay to confirm
specificity of NF-kB translocation to the nucleus.
ChIP assay
ChIP assay was carried out using the EpiQuik
TM tissue
chromatin immunoprecipitation kit (Epigentek Group, Brooklyn,
NY) according to the protocol recommended by the manufacturer
and modified for brain tissues. RVLM slices were cross-linked in
1% formaldehyde at room temperature for 15–20 min on a
rocking platform, followed by incubation with 0.125 M glycine for
5 min to stop the fixation. After washing using ice-cold PBS and
homogenizing the tissues, cell lysates were sonicated on ice until
the cross-linked chromatins are sheared to yield DNA fragments
between 200 and 1000 base pairs. The supernatant (sonicated
DNA) was diluted to the required volume with ChIP dilution
buffer at a 1:1 ratio, and 5 ml of the diluted supernatant was
removed to a 0.5 ml vial as ‘‘input’’ DNA and put on ice.
Sonicated DNA (500 mg) taken from each sample was incubated
with an anti-NFkB p65 antibody (Abcam, Cambridge, MA) at
room temperature for 60 min. Negative control was done by using
normal mouse-IgG. The precipitated DNA was added 5 M NaCl
and heated at 65uC to reverse histone-DNA crosslinks. The
immunocomplexes were treated with proteinase K, and DNA
fragments were purified for subsequent real-time PCR. ChIP data
were normalized to input DNA from each sample. The sequences
of specific nos II promoter primers were: 5’-AACACGAGGCT-
GAGCTGAAT-3’ (forward primer) and 5’-TACATGGCATGG-
GATTTTCC-3’ (reverse primer). The amplified products were
confirmed by running 1% agarose gels.
Enzyme-linked immunosorbent assay (ELISA)
We determined the protein levels of nitrotyrosine with
OxiSelect Nitrotyrosine ELISA Kit (Cell Biolabs, San Diego,
CA) following the protocol recommended by the manufacturer,
and modified for brain tissues. Protein extracted from RVLM was
first added to a nitrated BSA preabsorbed EIA plate. After brief
incubation, an anti-nitrotyrosine antibody was added, followed by
an HRP conjugated secondary antibody. The final absorbance of
reaction solution was determined by spectrophotometry using an
ELISA microtiter plate reader (Thermo Scientific, Waltham, MA)
using 450 nm as the primary wave length. Nitrotyrosine contents
were determined by comparing with a standard curve prepared
from predetermined nitrated BSA standards.
Statistical analysis
All values are expressed as mean 6 SEM. The averaged value
of MSAP or HR calculated every 20 min after administration of
test agents or vehicle, the sum total of power density for the LF
component in the SAP spectrum over 20 min, and changes in real-
time PCR products, protein expression or enzyme activity in
RVLM during each phase of experimental brain death, was used
for statistical analysis. One-way or two-way ANOVA with
repeated measures was used, as appropriate, to assess group
means. This was followed by the Scheffe ´ multiple-range test for
post hoc assessment of individual means. P ,0.05 was considered to
be statistically significant.
Supporting Information
Figure S1 Synthesis of NOS II via transcriptional
activation of NF-kB in RVLM. Representative gel depicting
NF-kB DNA binding detected by EMSA in nuclear extracts from
ventrolateral medulla of rats that received IV administration of
LPS (15 mg kg
21). In a supershift assay, nuclear extracts were
preincubated with an antiserum against NF-kB p50 subunit. A
competitive assay with the addition of 100-fold of unlabeled NF-
kB oligonucleotide was used to control for non-specific binding. ns
denotes non-specific binding.
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